{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920081,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Checkpoint inhibitor immunotherapy is a transformative treatment for advanced malignancies, but can be associated with numerous immune-related adverse events (irAEs). The majority of irAEs include those that closely resemble known cutaneous and neurocutaneous autoimmune or autoinflammatory diseases, such as scleroderma, psoriasis, and dermatomyositis. We present the case of a 63-year-old man with metastatic melanoma undergoing treatment with nivolumab who developed significant motor weakness, paresthesias of both hands, swollen fingers, and a pruritic rash over the face, chest, and upper back after two cycles. Creatine kinase was elevated. Electromyography revealed a myopathic pattern, muscle biopsy of the deltoid revealed an inflammatory myopathy, and skin biopsy showed interface dermatitis. There were no detectable autoantibodies except positive antinuclear antibody. He was diagnosed with immunotherapy-induced dermatomyositis, nivolumab was held, and he was treated with oral prednisone and intravenous immunoglobulin with overall improvement in myopathic and cutaneous symptoms. Dermatomyositis is an inflammatory myopathy with a characteristic dermatologic presentation that can occur spontaneously, as a paraneoplastic phenomenon, or as a drug reaction. This is the second known case of nivolumab-induced dermatomyositis. A review of the literature revealed seven total cases of immunotherapy-induced dermatomyositis. Functionally disabling autoimmune adverse effects of this severity would frequently persuade providers to discontinue immunotherapy in patients with metastatic disease.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000642","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T14:55:57Z","timestamp":1569423357000},"page":"313-316","source":"Crossref","is-referenced-by-count":28,"title":["Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature"],"prefix":"10.1097","volume":"30","author":[{"given":"Cory","family":"Kosche","sequence":"first","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Stout","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sosman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V.","family":"Lukas","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center"},{"name":"Department of Neurology"},{"name":"Lou and Jean Malnati Brain Tumor Institute, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Dermatology"},{"name":"Robert H. Lurie Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade.","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials.","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients.","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series.","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"9381","DOI":"10.2169\/internalmedicine.9381-17","article-title":"A case of advanced lung adenocarcinoma with nvolumab-associated dermatomyositis.","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies.","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2017.08.014","article-title":"Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission.","volume":"381","author":"Ogawa","year":"2017","journal-title":"J Neurol Sci"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy.","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jdcr.2018.08.006","article-title":"Wong-type dermatomyositis during anti-PD-1 therapy.","volume":"4","author":"Yu","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts.","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events (irAEs).","volume":"6","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:04:34Z","timestamp":1693627474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000642","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}